Clinical Trials Directory

Trials / Unknown

UnknownNCT01503645

Chinese Herb Nephropathy Epidemiology and Association With CYP2D6, CYP2C19, PXR, or MDR1 Polymorphism

Epidemiology of Chinese Herb Nephropathy and Its Association With CYP2D6, CYP2C19, PXR, or MDR1 Polymorphism

Status
Unknown
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
National Taiwan University Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

1. Chinese herb nephropathy (CHN), a kind of kidney failure caused by Chinese herbs, may be related to the a component called aristolochic acid (AA). 2. AA may form AA-DNA adducts and accumulate in the kidney and ureter and cause kidney failure and/or cancer 3. Different enzymes have been reported to detoxify plant alkaloids or other components. Genes that regulate the production of these metabolic enzymes may affect the chance of CHN. 4. By comparing the differences in the polymorphisms of these genes between patient with CHN and control, we may find the changes that play a significant genetic factors for CHN.

Conditions

Timeline

Start date
2006-05-01
First posted
2012-01-04
Last updated
2012-11-14

Locations

2 sites across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT01503645. Inclusion in this directory is not an endorsement.

Chinese Herb Nephropathy Epidemiology and Association With CYP2D6, CYP2C19, PXR, or MDR1 Polymorphism (NCT01503645) · Clinical Trials Directory